What is he best known for?
The fields of study he is best known for:
- Virus
- Gene
- Internal medicine
Virology, Immunology, Virus, Acquired immunodeficiency syndrome and Drug resistance are his primary areas of study.
His research investigates the connection between Virology and topics such as Molecular biology that intersect with problems in Cell culture.
His study in Viral load, Viral disease, Viremia, Lentivirus and Virus latency falls within the category of Immunology.
His Virus research incorporates elements of T cell, Peripheral blood mononuclear cell, Antibody and Sexual transmission.
In Acquired immunodeficiency syndrome, Douglas D. Richman works on issues like Pharmacotherapy, which are connected to MEDLINE.
His research investigates the link between Drug resistance and topics such as Drug that cross with problems in Disease.
His most cited work include:
- The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. (2708 citations)
- Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy (2466 citations)
- Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. (1818 citations)
What are the main themes of his work throughout his whole career to date?
Douglas D. Richman mainly focuses on Virology, Immunology, Virus, Acquired immunodeficiency syndrome and Zidovudine.
His studies in Virology integrate themes in fields like Antibody, Drug resistance and Reverse transcriptase.
Immunology and Peripheral blood mononuclear cell are frequently intertwined in his study.
His Virus research includes themes of RNA, Cell culture, In vitro and Molecular biology.
His Acquired immunodeficiency syndrome study combines topics in areas such as Clinical trial, Internal medicine, Pharmacotherapy, Disease and Cohort.
His research in Zidovudine intersects with topics in Lamivudine, AIDS-related complex, Indinavir and Chemotherapy.
He most often published in these fields:
- Virology (74.53%)
- Immunology (51.55%)
- Virus (40.37%)
What were the highlights of his more recent work (between 2013-2021)?
- Virology (74.53%)
- Immunology (51.55%)
- Viral load (20.37%)
In recent papers he was focusing on the following fields of study:
Douglas D. Richman mostly deals with Virology, Immunology, Viral load, Peripheral blood mononuclear cell and Viral replication.
His study in Virology focuses on Virus and Viremia.
His work in Immunology addresses issues such as Transcription, which are connected to fields such as Asymptomatic.
His Viral load research includes elements of Internal medicine, Interquartile range, Cohort study, Genotype and Drug resistance.
His Cohort study research includes elements of Acquired immunodeficiency syndrome, Incidence and Cohort.
His research in Peripheral blood mononuclear cell intersects with topics in Cytomegalovirus and Transplantation.
Between 2013 and 2021, his most popular works were:
- Defective proviruses rapidly accumulate during acute HIV-1 infection. (381 citations)
- Defective proviruses rapidly accumulate during acute HIV-1 infection. (381 citations)
- International AIDS Society global scientific strategy: towards an HIV cure 2016 (268 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Virus
- Internal medicine
Douglas D. Richman focuses on Immunology, Virology, Viral load, Viral replication and Peripheral blood mononuclear cell.
His study involves Immune system, Virus latency, CD8, T cell and Antibody, a branch of Immunology.
Virus and Emtricitabine are among the areas of Virology where the researcher is concentrating his efforts.
The concepts of his Viral load study are interwoven with issues in Cohort study, Resistance mutation, Lopinavir, Bone marrow and Lentivirus.
His Viral replication research integrates issues from Asymptomatic and Transcription.
Douglas D. Richman studied Peripheral blood mononuclear cell and RNA that intersect with DNA, CXCR3, In vitro, IL-2 receptor and Lymphatic system.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
